Imexpharm (STC:IMP) Margin of Safety % (DCF Earnings Based): -29.11% (As of Jun. 26, 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,900.00
GF Value ₫51,651.19
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Margin of Safety % (DCF Earnings Based)?

Imexpharm STC:IMP -1.38% 98 Margin of Safety % (DCF Earnings Based) is -29.11% as of Jun. 26, 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,651.19 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-26), Imexpharm's Predictability Rank is 2.5-Stars. Imexpharm's intrinsic value calculated from the Discounted Earnings model is ₫33226.38 and current share price is ₫42900.00. Consequently,

Imexpharm's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is -29.11%.

STC:IMP vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imexpharm Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Imexpharm's Margin of Safety % (DCF Earnings Based) falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Margin of Safety % (DCF Earnings Based) Calculation

Imexpharm's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(33226.38-42900.00)/33226.38
=-29.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of -29.11% mean?
Imexpharm (STC:IMP) has a Margin of Safety % (DCF Earnings Based) of -29.11% as of Jun. 26, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Imexpharm.
Is Imexpharm's Margin of Safety % (DCF Earnings Based) too high?
Imexpharm's current Margin of Safety % (DCF Earnings Based) is -29.11%. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Margin of Safety % (DCF Earnings Based) compare to ZTS?
Imexpharm's Margin of Safety % (DCF Earnings Based) of -29.11% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Imexpharm. Imexpharm's current Margin of Safety % (DCF Earnings Based) is -29.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,651.19, compared to a current price of ₫42,900.00 — trading 16.9% below its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is -29.11%. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Margin of Safety % (DCF Earnings Based) is -29.11% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,900.00 is trading 16.9% below its estimated GF Value™ of ₫51,651.19. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Margin of Safety % (DCF Earnings Based): -29.11%
  • GF Value™: ₫51,651.19 vs. price of ₫42,900.00 (16.9% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,900.00
Price
₫51,651.19
GF Value